Can-Fite Gets Approval For COVID-19 Clinical Trial For Piclidenoson In Israel

Israeli biotechnology company Can-Fite BioPharma Ltd. (CANF) announced Monday that it has received approval from the Institutional Review Board (IRB) at Rabin Medical Center to initiate a pilot clinical study of its drug candidate Piclidenoson for the treatment of moderate-to-severe symptoms in coronavirus (COVID-19) infected patients.

from RTT - Biotech https://ift.tt/2VnheKy
via IFTTT